Franklin Resources Inc. Buys 4,756 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Franklin Resources Inc. boosted its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 3.8% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 128,985 shares of the biopharmaceutical company’s stock after acquiring an additional 4,756 shares during the period. Franklin Resources Inc. owned 0.08% of TG Therapeutics worth $2,945,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Synovus Financial Corp acquired a new stake in shares of TG Therapeutics during the 3rd quarter worth $465,000. Teachers Retirement System of The State of Kentucky bought a new stake in TG Therapeutics during the third quarter worth about $1,039,000. Neo Ivy Capital Management acquired a new stake in TG Therapeutics during the third quarter worth about $2,358,000. Barclays PLC increased its holdings in TG Therapeutics by 83.9% in the 3rd quarter. Barclays PLC now owns 347,057 shares of the biopharmaceutical company’s stock valued at $8,117,000 after buying an additional 158,323 shares during the period. Finally, Castleark Management LLC acquired a new position in shares of TG Therapeutics in the 3rd quarter valued at approximately $3,948,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Trading Down 0.3 %

NASDAQ TGTX opened at $32.16 on Thursday. TG Therapeutics, Inc. has a twelve month low of $12.84 and a twelve month high of $36.84. The business’s fifty day moving average is $30.12 and its 200 day moving average is $24.30. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The company has a market cap of $5.01 billion, a price-to-earnings ratio of -321.57 and a beta of 2.25.

TG Therapeutics (NASDAQ:TGTX) last announced its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s revenue for the quarter was down 49.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.73 earnings per share. As a group, sell-side analysts expect that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

TGTX has been the topic of several analyst reports. The Goldman Sachs Group increased their price target on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. StockNews.com cut TG Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. HC Wainwright upped their price objective on TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. lifted their target price on TG Therapeutics from $30.00 to $43.00 and gave the company an “overweight” rating in a research report on Monday, November 25th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, TG Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $40.67.

Insider Buying and Selling at TG Therapeutics

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total transaction of $152,200.00. Following the transaction, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.50% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.